Newcastle University Single Cell Functional Genomics Unit (NUSCU)

纽卡斯尔大学(纽卡斯尔大学)在研究罕见疾病的分子基础方面有着良好的记录，这些记录是由具有明确表型和生物库组织的独特患者队列支持的，通过21项国家委托的NHS临床服务建立起来，我们与纽卡斯尔泰恩医院(Nuth)NHS基金会信托基金合作领导这些服务。我们在罕见的线粒体、神经肌肉和肌肉骨骼疾病、罕见的儿童癌症、罕见的免疫缺陷和新型细胞疗法方面的工作享誉国际，自2008年以来，每一项工作都得到了MRC、NIHR、惠康信托、欧盟、英国关节炎研究所(ARUK)、白血病和淋巴瘤研究所(LLR)以及英国癌症研究所(CRUK)的大量中心、奖学金和项目层面的支持。在过去的两年里，每个领域都独立地汇聚在单细胞功能基因组学和蛋白质组学方法上，以促进我们对发病机制的理解，从而解释为什么相同疾病的患者会发展成不同的临床表型，并以不同的方式对治疗做出反应。我们的目标是通过成立纽卡斯尔大学单细胞功能基因组学单位(NUSCU)，将专注于单细胞基因组、表观基因组学、转录和蛋白质组学特征的专业知识和基础设施整合在一起。该股将由学术领导，拥有一支专门的生物信息学团队和硬件，并通过新成立的北方单细胞联盟和CyTOF-UK用户组在全国范围内进行联系。NUSCU将由NU资助的专门设施经理管理，领导内部技术团队，建立一个成功的商业模式，将在3年内实现自我维持。

Newcastle University (NU) has a well-established track record studying the molecular basis of rare disease underpinned by unique cohorts of patients with defined phenotypes and biobanked tissue, built through 21 Nationally Commissioned NHS clinical services, which we lead in partnership with the Newcastle upon Tyne Hospitals (NUTH) NHS Foundation Trust. Our work on rare mitochondrial, neuromuscular & musculoskeletal diseases, rare childhood cancers, rare immune deficiencies, and novel cell therapies is renowned internationally, with each receiving substantial centre, fellowship, and programme level support from the MRC, NIHR, Wellcome Trust, European Union, Arthritis Research UK (ARUK), Leukaemia and Lymphoma Research (LLR), and Cancer Research UK (CRUK); >£100M combined since 2008. Over the last two years, each area has independently converged on single cell functional genomics and proteomic approaches to advance our understanding of pathogenesis and thus explain why patients with the same disorder develop different clinical phenotypes, and respond to treatments in different ways. We aim to bring together expertise and infrastructure focused on the genomic, epigenomic, transcriptomic and proteomic characterisation of single cells by forming the Newcastle University Single Cell Functional Genomics Unit (NUSCU). The Unit will be academically led, have a dedicated bioinformatics team and hardware, and interface nationally through the newly established Northern Single Cell Consortium and CyTOF-UK users group. NUSCU will be managed by a dedicated facilities manager funded by NU leading in in-house technical team, building on a successful business model which will lead to self-sustainability within 3-years.